Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

• HPV-16 and HPV-18 antibody titres [ Time Frame: Assessed one month after the last dose of vaccine when administered at different dosages and on different schedules ] [ Designated as safety issue: No ]
• Occurrence, intensity and causal relationship to vaccination of solicited local and general symptoms [ Time Frame: Within 7 days after each and any vaccination ] [ Designated as safety issue: No ]

• HPV-16/18 antibody titres assessed one month after the last dose of vaccine when administered at different dosages and on different schedules;
• Occurrence, intensity and causal relationship to vaccination of solicited symptoms within 7 days after each and any vaccination.

• Occurrence, intensity and causal relationship to vaccination of unsolicited symptoms [ Time Frame: Within 30 days after any vaccination ] [ Designated as safety issue: No ]
• Occurrence of serious adverse events [ Time Frame: Up to Month 7 and during the extended safety follow-up period (through Month 60) ] [ Designated as safety issue: No ]
• Occurrence of medically significant conditions [ Time Frame: Up to Month 7 and during the extended safety follow-up period (through Month 60) ] [ Designated as safety issue: No ]
• Occurrence of pregnancies and pregnancy outcomes [ Time Frame: Up to Month 7 and during the extended safety follow-up period (through Month 60) ] [ Designated as safety issue: No ]
• Changes in haematological and biochemical parameters from blood samples taken from all subjects [ Time Frame: At Month 0 and Month 7 ] [ Designated as safety issue: No ]
• HPV-16 and HPV-18 antibody titres (by ELISA) in all study groups and in all age strata [ Time Frame: Assessed one month after the last dose of vaccine (Month 7) ] [ Designated as safety issue: No ]
• HPV-16 and HPV-18 antibody titres [ Time Frame: Assessed one month after the second dose of vaccine in the alternative schedule groups ] [ Designated as safety issue: No ]
• HPV-16 and HPV-18 antibody titres (by ELISA) [ Time Frame: Assessed during the extended follow-up period (at Month 12, Month 18, Month 24, Month 36, Month 48, and Month 60) ] [ Designated as safety issue: No ]
• Number of subjects seroconverted for anti-HPV-16 and anti-HPV-18 antibody titers (by ELISA) [ Time Frame: Assessed during the extended follow-up period (at Month 12, Month 18, Month 24, Month 36, Month 48, and Month 60) ] [ Designated as safety issue: No ]

• Occurrence, intensity and causal relationship to vaccination of unsolicited symptoms within 30 days after any vaccination;
• Safety of GSK Biologicals' HPV vaccine 580299 throughout the entire study period (SAEs & medically significant conditions);
• HPV-16/18 antibody titres assessed one month after the last dose of vaccine in all study groups and in all age strata;
• HPV-16/18 antibody titres and seroconversion status assessed during the extended follow-up period.

HPV infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV vaccine (580299) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18), found in approximately 70% of all cervical cancers. In previous trials this vaccine has been found to be efficacious in the prevention of incident and persistent HPV-16/18 infections and associated cytological abnormalities and cervical dysplasia. In this partially-blind study, GSK Biologicals will evaluate the safety and immunogenicity of the HPV vaccine using an alternative schedule and an alternative dosing when administered in healthy young females aged 9 to 25 years, as compared to the standard HPV vaccine. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007. The protocol posting has been updated following a protocol amendment.

• Cervical Cancer
• Papillomavirus Infection

• Experimental: Group A
  Each group is stratified into three age strata: 9 - 14, 15 - 19 and 20 - 25 years of age.
  Intervention: Biological: GSK Bio's HPV vaccine 580299 (Cervarix TM)
• Experimental: Group B
  Each group is stratified into three age strata: 9 - 14, 15 - 19 and 20 - 25 years of age.
  Intervention: Biological: GSK Bio's HPV vaccine 580299 (Cervarix TM)
• Experimental: Group C
  Each group is stratified into three age strata: 9 - 14, 15 - 19 and 20 - 25 years of age.
  Intervention: Biological: GSK Bio's HPV vaccine 580299 (Cervarix TM)
• Experimental: Group D
  Each group is stratified into three age strata: 9 - 14, 15 - 19 and 20 - 25 years of age. 15-19 age group is considered as an active comparator.
  Intervention: Biological: GSK Bio's HPV vaccine 580299 (Cervarix TM)

Inclusion Criteria:

• Subjects who the investigator believes that they and/or their parents can and will comply with the requirements of the protocol should be enrolled in the study.
• A female subject between, and including, 9 and 25 years of age at the time of the first vaccination.
• Written informed consent/assent obtained from the subject prior to enrolment. For subjects above the legal age of consent, written informed consent must be obtained from the subject. For subjects below the legal age of consent, written informed consent from the subject's parents/legally acceptable representative, and written informed assent must be obtained from the subject.
• Healthy subjects as established by medical history and history-oriented clinical examination before entering into the study.
• Subject must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period (up to Month 24).
• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
• Concurrently participating in another clinical study, at any time during the study period (up to Month 24), in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
• Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after the first dose of vaccine. Planned administration/administration of routine vaccines, up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window.
• Pregnant or breastfeeding female.
• A woman planning to become pregnant or planning to discontinue contraceptive precautions during the study period, up to two months after the last vaccine dose.
• Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period (up to Month 24).
• Previous administration of components of the investigational vaccine.
• Cancer or autoimmune disease under treatment.
• Any medically diagnosed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• Hypersensitivity to latex.
• Acute disease at the time of enrolment.
• Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory tests.
• Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period (up to Month 24).